Navigation Links
Protein thought to promote cancer instead functions as a tumor suppressor

DALLAS July 7, 2008 A protein previously thought to promote colorectal cancer instead suppresses the growth of human cancer cells in culture, researchers at UT Southwestern Medical Center have found.

"This finding reshapes a fundamental model of how colorectal cancer arises," said Dr. Lawrence Lum, assistant professor of cell biology at UT Southwestern and senior author of the study, which appears online today and in a future issue of the Proceedings of the National Academy of Sciences.

Approximately 90 percent of colorectal cancers are caused by a biochemical malfunction that arises from mutations in a gene that activates a gene called TCF7L2, Dr. Lum said. As a result, TCF7L2 has been suspected of helping to trigger colorectal cancer.

In the current study, the researchers used a novel genetic screening approach known as RNAi mediated interference, or RNAi, to identify genes that contributed to this malfunction.

The researchers employed more than 80,000 small snippets of chemically synthesized RNAs (ribonucleic acids) known as "small interfering RNAs" or siRNAs, that are each capable of inactivating a specific gene. The researchers mixed these siRNAs with specially engineered human cancer cells that glowed when the cancer-causing malfunction is activated. When an siRNA made a cell glow, the researchers were able to flag the gene as a candidate cancer gene.

As the researchers examined the genes of interest more closely, they unexpectedly found that a gene called TCF7L2, which had been thought to boost malignant cell growth, instead suppressed it. When the gene was inactivated, human colorectal cancer cells grew more rapidly in culture and emitted a stronger glow.

"The function of TCF7L2 in cancer was previously determined from studies in animals but no one has genetically tested its role in human colorectal cancer cells before," said Dr. Lum, who is a Virginia Murchison Linthicum Scholar in Medical Research. "Prior to the advent of RNAi technology, this was very difficult to do in human cultured cells."

The next step is to understand more fully all the steps in the biochemical pathway involved in controlling the action of TCF7L2. This knowledge could then be used to identify new therapeutic targets for treating colorectal cancer. Therapeutic strategies derived from such studies may also be useful in treating type II diabetes, for which risk is strongly associated with mutations in TCF7L2, Dr. Lum said.

Dr. Lum noted that the findings about TCF7L2 show the effectiveness of this high throughput screening technique, which can quickly and systematically check many thousands of genes.

The success of this relatively new screening method for identifying candidate cancer genes demonstrates its usefulness to understanding human disease, Dr. Lum said.

"It's a way to analyze human gene action directly in human tissue at a genome-scale," he said.


Contact: Aline McKenzie
UT Southwestern Medical Center

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
Related Image:
Protein thought to promote cancer instead functions as a tumor suppressor
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: